Trial Profile
Trial of BioGaia's Lactobacillus reuteri Protectis drops in infants with colic in China
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2015
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Colic
- Focus Therapeutic Use
- 30 Apr 2015 New trial record
- 27 Apr 2015 Results published online in Antonie van Leeuwenhoek on 16 Apr 2015, according to a BioGaia media release.
- 27 Apr 2015 This study is the fifth positive colic study with Lactobacillus reuteri Protectis and the results confirm the positive results of earlier studies, according to a BioGaia media release.